MAZE Q3 2025 Earnings — Maze Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MAZEMaze Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$33M

Net Income

-$30M

EPS (Diluted)

$-0.66

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$422M

Total Liabilities

$43M

Stockholders' Equity

$379M

Cash & Equivalents

$317M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$0	$3M	-100.0%
Operating Income	-$33M	-$24M	-36.1%
Net Income	-$30M	-$25M	-21.6%